Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
The data is delayed by 15 minutes.
Description: ERBA Diagnostics, Inc., through its subsidiaries, develops, manufactures, and markets diagnostic test kits or assays, and automated systems that are used to aid in the detection of disease markers primarily in the areas of autoimmune, infectious diseases, clinical chemistry, hematology, and diabetes testing. It manufactures scientific and laboratory instruments, such as Mago 4, Mago 4S, and Mago Plus systems, which perform tests in an automated mode; sells other diagnostic products in Italy; and develops, manufactures, and markets diagnostic equipment, as well as raw materials, such as antigens that are used in the production of diagnostic kits. The company also develops, manufactures, and markets autoimmune reagents and research products for use by research laboratories and commercial diagnostic manufacturers. In addition, the company provides instruments for blood cell counting and blood analysis; supplies reagents and other consumable materials; sells diabetic testing products, including the DS5 instrument
See how to gain 20% in 14 sec with TrendsInvesting
|Shares Outstanding||EPS||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||-35.65%||Sales Growth - Q/Q||-19.25%||P/E|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-3%||ROE||-4.33%||ROI|
|Current Ratio||2.82||Quick Ratio||1.49||Long Term Debt/Equity||Debt Ratio||0.35|
|Gross Margin||47.31%||Operating Margin||-0.2%||Net Profit Margin||-2.95%||Dividend Payout Ratio|
|Cash From Financing Activities||Cash From Investing Activities||-290 K||Cash From Operating Activities||-150 K||Gross Profit||2.1 M|
|Net Profit||-1.02 M||Operating Profit||-670 K||Total Assets||24.49 M||Total Current Assets||16.85 M|
|Total Current Liabilities||5.98 M||Total Debt||1.94 M||Total Liabilities||7.53 M||Total Revenue||4.85 M|
|High 52 week||1.24||Low 52 week||0.48||Last close||0.5||Last change||0%|
|RSI||Average true range||Beta||0.57||Volume|
|Simple moving average 20 days||0%||Simple moving average 50 days||0%||Simple moving average 200 days||-14.11%|
|Performance Week||0%||Performance Month||0%||Performance Quart||0%||Performance Half||-7.41%|
|Performance Year||-57.63%||Performance Year-to-date||0%||Volatility daily||0%||Volatility weekly||0%|
|Volatility monthly||0%||Volatility yearly||0%||Relative Volume||0%||Average Volume|
|New High||New Low|
2019-05-27 07:44:18 | You Might Like Erbud S.A. WSE:ERB But Do You Like Its Debt?
2018-06-24 04:01:03 | Does Erbud SA’s WSE:ERB PE Ratio Warrant A Buy?
2018-05-05 03:27:33 | Where Erbud SA.’s WSE:ERB Earnings Growth Stands Against Its Industry
2018-04-12 11:15:17 | Is Erbud SA.’s WSE:ERB Balance Sheet A Threat To Its Future?
2016-02-26 13:06:00 | SHAREHOLDER ALERT: ERBA Diagnostics, Inc. _ERB_ is the Subject of a Legal Investigation
2016-01-29 09:43:00 | FINAL SHAREHOLDER NOTICE: Scott + Scott, LLP Reminds Investors that Monday, February 1, 2016 Is the Final Day to File Lead Plaintiff Papers in the Securities Lawsuit Against ERBA Diagnostics, Inc. - ERB
2016-01-27 08:14:10 | ERBA Diagnostics' Compliance Plan Accepted by NYSE MKT
2016-01-18 14:28:00 | Lifshitz & Miller Law Firm Announces Investigation of BofI Holding, Inc., Capstone Turbine Corporation, Dr. Reddy's Laboratories Ltd., ERBA Diagnostics, Inc., Identiv, Inc., Osiris Therapeutics, Inc., and XBiotech Inc.
2016-01-04 17:38:00 | DEADLINE ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 from Investment in ERBA Diagnostics, Inc. to Contact Brower Piven before the Lead Plaintiff Deadline in Class Action Lawsuit
2015-12-30 21:16:00 | DEADLINE APPROACHING: Lundin Law PC Announces Securities Class Action Lawsuit against ERBA Diagnostics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
2015-12-28 19:34:00 | IMPORTANT INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against ERBA Diagnostics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm